Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827780 | 0.95 | HTT (0.62) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL4922153 | 0.95 | HTT (0.62) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL31267470 | 0.91 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL3688021 | 0.91 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL866062 | 0.90 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL1204120 | 0.88 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL8515238 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL31267447 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL5940566 | 0.85 | TSHR (0.70) | ALDH1A1KDM4EHPGDHTTTSHR | |
| SCHEMBL8515277 | 0.85 | HDAC3 (0.56) | ALDH1A1KDM4EHPGDHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3558950-B1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | OLIGOMERIX, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3558950-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118791-A9 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2018118791-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| US-6492364-B1 | Triazolo and derivatives as chemokine inhibitors | TORAY INDUSTRIES, INC. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
| EP-0855387-A1 | 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | ALDH1A1 3235/4885KDM4E 3341/4885HPGD 1742/4885 |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | MAPT, PSEN1, APP | ALDH1A1 3381/4885KDM4E 2885/4885HPGD 1765/4885 |
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | ALDH1A1 3235/4885KDM4E 3341/4885HPGD 1742/4885 |
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | ALDH1A1 1248/4885KDM4E 2385/4885HPGD 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.